Viking Therapeutics is a clinical-stage biotech company whose value rests on VK2735, an experimental obesity drug now in Phase 3 trials as both a weekly injection and a daily pill. It had $960m of cash and short-term investments at the end of September after a large September financing, but it has no products on sale and lost $183.2m in the third quarter alone.
What Viking does
Viking's shares trade on Nasdaq as VKTX. The company develops medicines for metabolic and endocrine diseases, and it does not yet sell anything.
Its lead drug, VK2735, acts on two gut hormone receptors, GLP-1 and GIP. Viking is testing it in two forms: an injection given once a week and a tablet taken once a day. Behind it sits VK3019, an amylin agonist, which works through another hormone pathway being explored for weight loss. The company also lists VK2809, an oral drug for metabolic and liver disease, and VK0214, for the rare disorder X-linked adrenoleukodystrophy, but it gave no update on either with its latest results.
Viking Therapeutics: share price, chart and news
The pipeline in Phase 3
| Programme | Stage | Size and design | Timing |
|---|---|---|---|
| VANQUISH-1 (injection, obesity) | Phase 3, enrolled | About 4,500 adults, 78 weeks | Completion expected in 2027 |
| VANQUISH-2 (injection, obesity with type 2 diabetes) | Phase 3, enrolled | About 1,000 adults, 78 weeks | Completion expected in 2027 |
| SUNRISE-1 and SUNRISE-2 (pill) | Phase 3, started October 2026 | 560 adults each, 68 weeks | Not yet given |
| Maintenance study, Part 2 | Started | About 195 adults | Results expected in 2027 |
| VK3019 | Phase 1 | Single ascending dose study | Completion expected later in Q4 2026 |
The VANQUISH trials test weekly doses of 7.5 mg, 12.5 mg and 17.5 mg against placebo, with percentage change in body weight as the main goal. Viking says it enrolled about 4,500 patients in VANQUISH-1 within about five months. Extension studies of up to 52 more weeks are due to begin in the first quarter of 2027, and the VANQUISH-1 extension will include every-other-week and monthly dosing. Results from the extensions are expected in 2028.
The SUNRISE trials test daily pills of 27.5 mg, 35 mg and 55 mg. In an earlier Phase 2 study, the pill produced weight loss of up to 12.2% after 13 weeks, and up to 80% of treated people lost at least 10% of their weight, against 5% on placebo. VANQUISH-2, for people who also have type 2 diabetes, took about nine months to enrol.
In September, Part 1 of the maintenance study showed that people who switched from weekly injections to every-other-week doses kept 83% to 97% of their weight loss over 12 weeks, and those on monthly doses kept 82% to 90%, against 61% on placebo. The arms were small, at about 10 to 16 people each. Part 2, with about 195 adults, tests oral maintenance dosing.
The latest numbers
| Measure | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Research and development | $166.8m | $90.0m | $432.7m | $191.5m |
| General and administrative | $20.3m | $8.6m | $51.1m | $37.1m |
| Net loss | $183.2m | $90.8m | $469.5m | $202.0m |
| Net loss per share | $1.55 | $0.81 | $4.03 | $1.80 |
Research spending almost doubled from a year earlier as the large Phase 3 trials enrolled patients. The quarterly net loss doubled too.
Cash, shares and debt
Balance sheet, 30 September 2026
- $960m cash, cash equivalents and short-term investments
- 127.5m shares outstanding on 15 October
- $258.75m of 2.00% convertible notes due 2032
Cash rose from $706m at the end of 2025 because of the September financing, which raised about $575m gross and about $550m net. Viking sold 9,035,714 shares at $35.00, with Morgan Stanley and J.P. Morgan leading the deal, and issued $258.75m of convertible notes that pay 2.00% a year and mature on 15 October 2032. The notes convert at about $50.75 a share, roughly 45% above the share sale price, so full conversion would create about 5.1m more shares.
Viking can settle conversions in cash, shares or both, and from 22 October 2029 it can redeem the notes if its shares trade above 130% of the conversion price under set conditions. The money is earmarked for VK2735, VK3019 and general research and corporate costs. The company said the money gives it the runway to run several Phase 3 trials.
The $960m is a little more than five times the third-quarter net loss, although accounting losses and cash spending are not the same. How long it lasts will depend on the cost of four Phase 3 trials, their extension studies and any preparation for a launch.
Risks and what to watch
Main risks
- Trial risk. VK2735 has not yet reported Phase 3 results, and late-stage trials can fail or show more side effects than earlier ones.
- Heavy losses. Viking lost $469.5m in nine months with no revenue.
- Dilution and debt. The September share sale added about 9m shares, the notes could add about 5.1m, and further raises may be needed before any launch.
- Competition. Obesity drugs from much larger companies are already on the market, and many rivals are developing new ones.
- Small maintenance data. The every-other-week and monthly results come from small groups over 12 weeks.
| When | What |
|---|---|
| 14 to 15 November 2026 | ObesityWeek posters on VANQUISH-2 baseline data and earlier VENTURE results |
| Later in Q4 2026 | Completion of the VK3019 single ascending dose study |
| Q1 2027 | Start of VANQUISH extension studies and a 28-day VK3019 multiple ascending dose study |
| 2027 | Completion of VANQUISH-1 and VANQUISH-2, and maintenance Part 2 results |
| 2028 | Results from the VANQUISH extension studies |
Sources
- Viking Therapeutics (Form 8-K, Exhibit 99.1): Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (2026-10-28)
- U.S. Securities and Exchange Commission (EDGAR): Viking Therapeutics, Inc. Form 10-Q cover page (shares outstanding) (2026-10-29)
- Viking Therapeutics (Form 8-K, Exhibit 99.1): Viking Therapeutics Announces Positive Top-Line Results from VK2735 Maintenance Study (2026-09-22)
- U.S. Securities and Exchange Commission (EDGAR): Viking Therapeutics, Inc. Form 8-K: underwriting agreements, common stock offering and 2.00% convertible senior notes due 2032 (2026-09-28)








